Charity Breast Cancer Now has described the failure to negotiate a fair price of Enhertu as “utterly heartbreaking”.

The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) says that talks with the makers ...

AZ and Daiichi Sankyo have said that NICE's decision on Enhertu exposes how new methods and processes the agency uses to ...

Women with incurable breast cancer in England and Wales will not be offered a life-extending drug on the health service after ...

The National Institute for Health and Care Excellence (Nice) said it is "extremely disappointed" it will be unable to ...

The UK's drug pricing body has affirmed its earlier decision not to recommend coverage of AstraZeneca and Daiichi Sankyo’s ...

Breast cancer patients in England and Wales will not have access to the drug after pricing negotiations failed between NICE and drugmakers.